R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation

The R&D Race: Regeneron vs. Bio-Techne

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation have been at the forefront of this race. Since 2014, Regeneron has consistently outpaced Bio-Techne, with its R&D expenses growing by approximately 250% by 2023. In contrast, Bio-Techne's R&D spending increased by about 212% over the same period.

A Decade of Growth

Regeneron's R&D investment peaked in 2023, reaching nearly $4.4 billion, a testament to its commitment to innovation. Meanwhile, Bio-Techne's spending, though significantly smaller, showed a steady increase, reaching nearly $97 million in 2024. This disparity highlights the different scales at which these companies operate, yet both are crucial players in advancing biotechnology.

The Missing Year

Interestingly, 2024 data for Regeneron is missing, leaving a gap in the narrative. This absence invites speculation about future trends and strategic shifts in their R&D focus.